Provided is a fusion protein comprising AXL receptor tyrosine kinase (AXL protein) and MAP3K12 binding inhibitory protein 1 (MBIP protein), a composition for diagnosing a cancer comprising a substance interacting with the fusion protein, a method of providing information for diagnosing a cancer using the fusion protein, a composition for preventing and/or treating a cancer comprising an inhibitor against the fusion protein, and a method for screening an anticancer agent using the fusion protein.
